GlassScriptPhysician profile
Raghad H Said
NPI 1659318103
$47,689.72
in general payments reported to CMS, 2019-2025
15 companies · $18K in 2025
The $18K reported for 2025 was more than what 97% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $332 · 2021: $395 · 2022: $298 · 2023: $2,431 · 2024: $26K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $23K · Consulting Fee: $15K · Travel and Lodging: $4,287 · Food and Beverage: $4,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $22,550.00 |
| Consulting Fee | $15,300.00 |
| Travel and Lodging | $4,287.48 |
| Food and Beverage | $4,142.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $44,855.34 | 2019-2025 | Impella |
| Edwards Lifesciences Corporation | $1,621.66 | 2021-2024 | Hemosphere |
| Portola Pharmaceuticals, LLC | $254.04 | 2019 | |
| Shionogi INC | $241.52 | 2024 | Fetroja |
| Daxor Corporation | $127.65 | 2024 | Bva-100 |
| Astrazeneca Pharmaceuticals LP | $121.60 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.97 | 2021 | |
| Abbott Laboratories | $104.71 | 2024 | 2nd Gen Centrimag Primary Console |
| Janssen Pharmaceuticals, INC | $80.72 | 2020 | |
| Nxstage Medical, INC. | $77.98 | 2025 | Nxstage System One |
| Boston Scientific Corporation | $22.62 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.63 | 2023 | Lifevest |
| Kci USA, INC. | $19.73 | 2022 | |
| La Jolla Pharmaceutical Company | $17.51 | 2024 | Giapreza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.04 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raghad Said listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.